Cargando…

Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort

Clinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kordes, Maximilian, Yu, Jingru, Malgerud, Oscar, Gustafsson Liljefors, Maria, Löhr, J. -Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769947/ https://www.ncbi.nlm.nih.gov/pubmed/31500236 http://dx.doi.org/10.3390/cancers11091326

Ejemplares similares

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer
por: Malgerud, Linnéa, et al.
Publicado: (2017)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study
por: Kawamura, Hidetaka, et al.
Publicado: (2020)

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2015)

Gastric Mucosal Abnormality and Risk of Pancreatic Cancer: A Population-Based Gastric Biopsy Cohort Study in Sweden
por: Yu, Jingru, et al.
Publicado: (2021)

Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis
por: Vujasinovic, Miroslav, et al.
Publicado: (2020)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Extracellular vesicles are the primary source of blood‐borne tumour‐derived mutant KRAS DNA early in pancreatic cancer
por: Hagey, Daniel W., et al.
Publicado: (2021)

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
por: Takada, Ryoji, et al.
Publicado: (2021)

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)

ASO Author Reflections: The Impact of Minimally Invasive Surgery on the Completion Rate of the Perioperative Chemotherapy Protocol in Gastric Cancer
por: Tsekrekos, Andrianos, et al.
Publicado: (2023)

Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study
por: Tsekrekos, Andrianos, et al.
Publicado: (2023)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
por: Nie, Duorui, et al.
Publicado: (2021)

Real-world analysis of survival benefit of surgery and adjuvant therapy in elderly patients with colorectal cancer
por: Zhang, Lei, et al.
Publicado: (2023)

134 Comparing Real-World Impacts of Cohorts using the Translational Science Benefits Model
por: Miovsky, Nicole, et al.
Publicado: (2023)

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018)

Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
por: Jiménez Fonseca, Paula, et al.
Publicado: (2017)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer
por: He, Chaobin, et al.
Publicado: (2020)

Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Ji, Xuemei, et al.
Publicado: (2013)

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
por: Kang, Nai-Wen, et al.
Publicado: (2022)

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
por: Cedres, Susana, et al.
Publicado: (2021)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1)
por: Arcelli, Alessandra, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival
por: Antonini, Marcelo, et al.
Publicado: (2023)

Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients
por: Gherasim-Morogai, Natalia, et al.
Publicado: (2022)

ePCR: an R-package for survival and time-to-event prediction in advanced prostate cancer, applied to real-world patient cohorts
por: Laajala, Teemu D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cut9la8t1h8b61vqltlbamdbd1